Table 1.

Neoadjuvant chemotherapy phase II trials.

Reference	Chemotherapy	N	N2	ORR (% total)	Surgery (% total)	R0 (% surgery)	PCR (% total)	Survival
Martini et al. (10)	MVP	41	41	73	68	75	20	3 years 34%, 3 years 54% (R0),
Vokes et al. (11)	EVP	27	NR	48	15	NR	0	Median 8 months
Pujol et al. (12)	EPI	33	31	70	61	90	15	18 months 30%, median 10 months
Burkes et al. (13)	MVP	39	39	64	56	82	8	3 years 26%, median 19 months
Martini et al. (14)	MVP	136	136	77	84	78	14	3 years 28%, median 19 months; 3 years 41% (R0)
Darwish et al. (15)	PE	46	46	80	72	85	9	2 years 53%, median 25 months
Sugarbaker et al. (16)	VP	74	74	NR	85	37	0	3 years 23%, 3 years 46% (R0)
Elias et al. (17)	P, 5-FU	34	34	65	82	75	18	Median 18 months
van Zandwijk et al.a (18)	GP	47	47	70	NS	NS	NS	Median 19 months
Betticher et al. (19)	DP	90	90	66	83	48	16	EFS 15 months, median 33 months
O’Brien et al.a (20)	CT	52	52	64	NS	NS	NS	1 year 68%, median 21 months
De Marinis et al. (21)	GTP	49	49	74	59	93	16	1 year 85%, median 23 months
Cappuzzo et al. (22)	GP	129	88	62	31	95	2	1 year 74%, median 19 months
Burkes et al. (23)	MVP or VP	65	65	68	72	75	5	1 year 66%, median 19 months; 5 years 29%
Biesma et al.a (24)	DP	46	46	39	NS	NS	NS	1 year 65%, median 16 months
Garrido et al. (25)	GDP	136	69	53	66	69	6	3 years 37%, median 16 months; 5 years 41% (R0)
Chaft et al. (26)	Bev, DP + Bev	50	NR	40	88	82	NR	3 years 64%
Ou et al. (27)	C, Pem, Bev	42	36	42	74	71	NR	1 year 56%, median EFS 15.4 months

Bev, bevacizumab; C, carboplatin; D, docetaxel; EFS, event-free survival; E, etoposide; 5-FU, 5-fluorouracil; G, gemcitabine; I, ifosfamide; M, mitomycin-C; NR, not reported; NS, not significant; ORR, overall response rate P, cisplatin; V, PCR, pathologic complete response; Pem, pemetrexed; T, paclitaxel; vinblastine/vindesine.

^aPatients in this trial were randomized to surgery or radiation after induction chemotherapy as part of the EORTC 08941.